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Background: Among patients with relapsing-remitting multiple sclerosis, relapses are associated with increased
disability and decreased quality of life. Relapses are commonly treated with corticosteroids or left untreated. We
aimed to better understand patient perceptions of the adequacy of corticosteroids in resolving relapse symptoms.
Methods: We examined self-reported data from 4482 participants in the North American Research Committee
on Multiple Sclerosis (NARCOMS) Registry regarding evaluation, treatment, and recovery from relapses. Pearson’s
chi-square test was used to analyze categorical variables, while logistic regression was used to assess factors
associated with patients’ perceptions.
Results: Forty percent (1775/4482) of respondents were simply observed for disease worsening, whereas
25% (1133/4482) were treated with intravenous methylprednisolone (IVMP) and 20% (923/4482) with oral
corticosteroids; additional treatments included adrenocorticotropic hormone, plasmapheresis, intravenous
immunoglobulin, and others. Among patients who responded to questions about their most recent relapse,
32% (363/1123) of IVMP-treated and 34% (301/895) of oral corticosteroid-treated patients indicated their
symptoms were worse one month after treatment than pre-relapse, as did 39% (612/1574) of observation-only
patients; 30% (335/1122) of IVMP-treated patients indicated their treatment made relapse symptoms worse
(13% [145/1122]) or had no effect (17% [190/1122]), as did 38% (340/894) of oral corticosteroid-treated patients
(worse, 13% [116/894]; no effect, 25% [224/894]) and 76% (1162/1514) of observation-only patients (worse,
17% [264/1514]; no change, 59% [898/1514]).
Conclusions: Overall, patients with relapsing multiple sclerosis who receive treatment report better outcomes
than those who are simply observed. However, a sizeable percentage of patients feel that their symptoms
following corticosteroid treatment are worse than pre-relapse symptoms and that treatment had no effect or
worsened symptoms. Patient perceptions of relapse treatment deserve more attention, and more effective
treatment options are needed.
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Relapses are the hallmark of multiple sclerosis (MS), with
approximately 80% of MS cases diagnosed as relapsing-
remitting (RRMS) at onset [1,2]. Symptoms of relapses
vary and commonly include sensory disturbances, fatigue,
and/or motor impairment; symptoms may last from
several days to several weeks and generally resolve over
time, with or without treatment, but recovery may be
incomplete [1]. A substantial proportion (up to 49%) of
RRMS patients exhibit residual deficits on the Expanded
Disability Status Scale (EDSS) after relapses, including
patients who received treatment [3,4]. Further, relapses
have substantial emotional and psychosocial effects [5,6]
and significantly increase economic costs, including sub-
stantial indirect costs associated with reduced productivity
and declines in functional ability [7].
Although mild relapses may be managed with observa-
tion only, severe symptoms and significant functional
limitation generally prompt treatment with high-dose
corticosteroids [8]. Such treatment shortens the time to
recovery from a relapse [9]; however, evidence that this
improves the extent of recovery is lacking, and corticoste-
roids are not tolerated by all patients. Adverse effects of
acute treatment with high-dose corticosteroids may include
gastrointestinal disturbances, headache, increased appetite,
hyperglycemia, edema, effects on mood, anxiety, insomnia,
and, rarely, psychosis; avascular necrosis of bone or hypo-
kalemia are also possible but occur infrequently [8].
Patient-reported outcomes, including health-related qual-
ity-of-life (HRQoL) measures, are increasingly attracting
interest within MS research. Patient-reported HRQoL
may predict disability in MS [10] and is associated with
magnetic resonance imaging (MRI) lesion burden and
brain atrophy [11]. However, patients’ perceptions of
recovery from relapses, specifically with regard to the
effects of treatments, have not received as much attention.
Further, patients’ perceptions of improvement do not
necessarily correlate with clinical measures. For example,
one study found that, 6 weeks after treatment with intra-
venous methylprednisolone (IVMP), 9% to 23% of patients
had significant improvement on clinician-rated measures,
but on patient self-report, only 5% indicated a complete
return to baseline [12].
Our goal was to quantify the subjective patient ex-
perience following treatment with corticosteroids, via a
retrospective analysis of data from the North American
Research Committee on Multiple Sclerosis (NARCOMS)
Registry. We also investigated the relationship between
patients’ characteristics and perceived relapse outcomes.
Methods
Registry and participants
The NARCOMS Registry is a long-term project of the non-
profit Consortium of Multiple Sclerosis Centers (CMSC)[13,14], designed to promote MS research. Patient parti-
cipation in NARCOMS is voluntary. NARCOMS was
founded by the CMSC in 1993 and, over the years, has
been supported by grants and in-kind services from the
United Spinal Association, the Paralyzed Veterans As-
sociation, and the National Multiple Sclerosis Society,
and by unrestricted grants from Berlex, Biogen Idec,
Immunex, EMD Serono, and Teva Neuroscience. It has
registered more than 36,000 participants to date [15].
Registry participants are asked to complete 2 update
questionnaires annually to provide current demographic
and clinical information. The NARCOMS Registry proto-
col is approved by the Institutional Review Board at
the University of Alabama at Birmingham. Participants
give written consent for their information to be used for
research purposes.
Access to the limited de-identified dataset was obtained
through a research agreement between the Consortium
of MS Centers (CMSC)/NARCOMS and Questcor Phar-
maceuticals. The NARCOMS registry operates under the
oversight of the Institutional Review Board at University
of Alabama at Birmingham.
Outcome measures
This analysis included data derived from the spring of
2007 update questionnaire, which included questions per-
taining to relapse management, disease-modifying therapies
(DMTs), and symptomatic therapies. Participants identified
the type of treatment they received for their most recent
relapse (options were: observation only, IVMP, IV dexa-
methasone, oral MP, oral dexamethasone, oral prednisone,
intramuscular [IM] adrenocorticotropin hormone [ACTH],
IV immunoglobulin [IG], plasmapheresis, and other) and
were asked to evaluate their response to treatment. Only
those responders who reported having experienced a re-
lapse were included in this study; for questions regarding
the most recent relapse, there was no restriction regarding
the time frame when that relapse occurred.
Two specific questions were explored in detail for this
analysis. The first was used to evaluate patients’ percep-
tions of recovery in terms of symptom improvement or
resolution: “As compared to the symptoms just before
my most recent relapse, my overall MS symptoms 1
month after the relapse treatment were…” The second
was used to evaluate patients’ perceptions of the effect of
treatment on facilitating or improving recovery: “As a
result of the treatment, my recovery was…” Response
choices for both questions were on a 7-item Likert-type
scale: much worse, worse, a little worse, no change, a little
better, better, or much better.
Statistical analysis
Pearson’s chi-square test was used to compare the distri-
butions of categorical variables and to test for statistical
Table 1 Demographic and clinical characteristics
of respondents
Characteristic








Sex (n = 4482) n (%)
Male 854 (19)
Female 3628 (81)




Months since last relapse Mean (SD)
Overall (n = 4367) 11.7 (9.8)
Patients with 1–4 relapses (n = 1389) 14 (10.8)
Patients with 5–9 relapses (n = 1440) 12 (9.4)
Patients with ≥10 relapses (n = 1502) 10 (8.7)
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to assess factors associated with patients’ perceptions of
treatment efficacy using all participants who responded to
relevant survey questions. For this analysis, the 7 response
choices were collapsed into 2 categories for each question.
For the question on symptoms, responses were catego-
rized as worse (responses = much worse, worse, a little
worse) or not worse (responses = no change, a little
better, better, much better); for the question on treatment,
responses were categorized as not better (responses =
much worse, worse, a little worse, no change) or better
(responses = a little better, better, much better). The fac-
tors evaluated were sex (male vs. female), number of total
lifetime relapses (1–4, 5–9, or ≥10 [i.e., based on tertiles]),
time since most recent relapse (months [as a continuous
variable]), treatment (IV corticosteroids, oral corticoste-
roids, other treatment [IM ACTH, IVIG, plasmapheresis,
unspecified], or observation), and treatment location
(home/nonclinical site, clinical site, or unspecified site).
Prior to the fitting of logistic regression models, the
distributions of each categorical factor were reviewed
in order to confirm that the sample size for each level
was sufficiently large. In addition, the distributions of
each quantitative factor were reviewed to ensure that there
were no extreme outliers. The initial logistic regression
model for each of the two endpoints of interest included
main effects for each of the above factors. Based on the
use of individual and joint tests of the effects of selected
factors, a reduced model identified factors significantly
associated with patient-reported symptom resolution
and treatment effects. Statistical significance was set at
p < 0.05. SAS version 9.1 was used for all analyses (SAS
Institute Inc., Cary, N.C.).
Results
Demographic and clinical characteristics
A total of 10,688 respondents (of 16,590 enrollees active
at the time) completed the spring 2007 update survey
[16]. The study population for this analysis included
4482 respondents who reported having experienced a re-
lapse in 2004, 2005, 2006, or 2007 (Table 1).
Relapse assessments, management, settings, and follow up
Prior to the decision regarding treatment, approximately
62% of relapsing patients were examined by a physician
and 18% by a physician’s assistant or nurse, 36% consulted
with a health care provider by phone, 25% had an MRI,
18% had an investigation for a urinary tract infection, and
5% had an imaging study. Patients could choose more
than one option; there was no option for “did not seek
treatment,” so compiled data represent only the portion of
patients who sought treatment.
A total of 1775/4482 (40%) patients reported their re-
lapse was managed with observation only. Collectively,IV and oral corticosteroids were the most frequently
reported active treatments, the most common of which
was IVMP (n =1133; 25% of total respondents) (Figure 1).
Significant differences between males and females were
noted in the observation-only (46% males, 38% females;
p < 0.0001 for distribution of yes/no responses), IVMP
(21%, 26%; p = 0.0017), and oral prednisone groups
(12%, 17%; p = 0.0003). The age distribution of patients
treated with IV steroids differed significantly from the
age distribution of those not treated with IV steroids
(p < 0.0001). Treatment with both IV and oral steroids
was more likely than not at younger ages (Table 2).
Treatment settings varied, with 28% receiving treatment
in a physician’s office, 17% in an outpatient clinic, 10% in
an inpatient setting, 7% in an emergency room, 2% in an
urgent care center, and 40% in home/nonclinical settings
(patients could select more than 1 option). IVMP was
the most common treatment in emergency room (109/
316; 34%), outpatient clinic (342/766; 45%), and inpatient
settings (190/427; 45%); while observation only was the
most common management approach in urgent care
centers (28/71; 39%) and physicians’ offices (614/1274;
48%). Observation only, IVMP, and oral prednisone
were almost equally prescribed for patients in home/
nonclinical settings (504 [28%], 510 [28%], and 467



























Figure 1 Distribution of relapse treatments among patients with a relapse (n=4482); patients could chose more than 1 option.
ACTH, adrenocorticotropic hormone; Dex, dexamethasone; IM, intramuscular; IV, intravenous; IVIG, intravenous immunoglobulin; IVMP, intravenous
methylprednisolone; MP, methylprednisolone; Pred, prednisone.
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follow-up with a physician, 20% were referred to physical
therapy, 12% had a change in DMT, 7% were referred to
occupational therapy, and 2% were referred to speech
therapy (7% of patients indicated other responses, which
included MRI, referral to other specialists or rehabilita-
tion, medication change, urological testing, or none).
To better understand the circumstances associated with
the MS relapse experience for males as compared to
females, a focused analysis on how sex impacted treat-
ment factors was performed. Males were more likely
than females to be simply observed for their relapse
(p < 0.0001), less likely than females to be treated with
IVMP (p = 0.0017), and less likely than females to be
treated with oral prednisone (p = 0.0003). Although the
distributions of time since last relapse and number of
relapses were similar for males and females, a greater
proportion of males were in older age categories than
females (p < 0.001). When experiencing a relapse, males
and females utilized urgent care centers, the emergency
room, and the physician’s office to the same degree.
However, females were more likely to consult theirTable 2 Number (%) of patients reporting treatment with
IV or oral steroids based on age
IV Steroids Oral steroids
Age category Yes No Yes No
20-34 113 (9.5) 172 (5.2) 65 (7.2) 220 (6.2)
35-44 332 (27.8) 683 (20.8) 240 (26.6) 775 (21.7)
45-54 484 (40.4) 1311 (39.9) 366 (40.5) 1429 (40)
55-64 226 (18.9) 901 (27.4) 192 (21.2) 935 (26.2)
65-74 35 (2.9) 179 (5.5) 37 (4.1) 177 (5)
75-90 6 (.5) 37 (1.1) 4 (0.4) 39 (1.1)
Total (n) 1196 3283 904 3575doctor or nurse by phone (p < 0.0001). Males and females
had the same likelihood of following up with a physician.
Overall response to relapse management
In response to the question regarding symptoms at 1
month after relapse treatment, for the overall population
(n = 4238), 35% of patients reported worse symptoms,
25% reported no change, and 40% reported symptom
improvement (Figure 2A). In response to the question
regarding effect of treatment (including observation) on
recovery, for the overall population (n = 4157), 15% of
patients reported that treatment made their recovery
worse, 37% reported no change, and 48% reported treat-
ment made recovery better (Figure 2B).
The distribution of responses (worse, no change, or
better) reflected less favorable outcomes for males com-
pared with females for patient-reported symptom im-
provement (males: 43%, 25%, 32%; females: 33%, 25%,
43%; p < 0.0001) and treatment success (males: 19%, 41%,
41%; females: 14%, 36%, 49%; p = 0.0001). The time since
last relapse trended toward being longer among those who
rated their symptoms as better and among those who
rated their treatment efficacy as better, than among those
who indicated no change or worse for each question (data
not shown).
A relationship between treatment location and symp-
toms ratings was seen for emergency room, urgent care
center, outpatient clinic, and inpatient services, and be-
tween location and treatment efficacy in all settings (ie, the
distribution of response for any given treatment setting
was statistically significantly different compared with
the distribution among all patients not treated in that
setting) (Table 3).
For each treatment subgroup (ie, observation only,
IVMP, oral corticosteroids, and other), there was an effect





















































All patients (n=4157) Observation only (n=1514) Corticosteroid-treated (n=1718) 
Figure 2 Subjective ratings of (A) symptom improvement and (B) effect of treatment on recovery among all patients who experienced
a relapse, and subgroups of interest (ie, patients whose relapses were managed with observation only or patients treated with
corticosteroid). A. Symptom improvement, based on responses to the following question: “As compared to the symptoms just before my most
recent relapse, my overall MS symptoms 1 month after the relapse treatment were…” B. Effect of treatment on recovery, based on responses to
the following question: “As a result of my treatment, my recovery was…”.
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nificantly different compared with the distribution among
all patients not receiving that intervention) (Table 4).
Outcomes among patients whose relapses were managed
with corticosteroids or observation only
Because corticosteroids (as a whole) were the most com-
mon active treatment, we further examined outcomesTable 3 Number (%) of patients reporting worse, no change,
Setting Symptom improvement
n Worse No change Improved
Home/nonclinical site 1762 614 (35) 418 (24) 730 (41)
Physician’s office 1252 452 (36) 306 (24) 494 (39)
Hospital outpatient 754 258 (34) 139 (18) 357 (47)
Hospital inpatient 422 178 (42) 62 (15) 182 (43)
Emergency room 303 134 (44) 50 (17) 119 (39)
Urgent care center 70 34 (49) 10 (14) 26 (37)
p-values are for effect of location on outcome from Pearson’s chi-square test; specif
subjects not in that row.among these patients. Responses for the overall cortico-
steroid subgroup (ie, patients treated with any IV or oral
steroid) are shown in Figure 2A and 2B. We further ana-
lyzed subgroups treated with IVMP or oral corticosteroids
(given that IVMP was the most common IV corticosteroid
treatment reported here and in clinical trials, we excluded
the small numbers of patients receiving other IV cortico-
steroids to strengthen our ability to draw conclusions fromor improved outcomes based on treatment setting
Effect of treatment on recovery
p-value n Worse No change Improved p-value
0.3427 1755 255 (15) 569 (32) 931 (53) <0.0001
0.4855 1238 196 (16) 494 (40) 548 (44) 0.0173
<0.0001 745 108 (15) 192 (26) 445 (60) <0.0001
<0.0001 417 102 (24) 85 (20) 230 (55) <0.0001
0.0002 292 84 (29) 58 (20) 150 (51) <0.0001
0.0264 62 18 (29) 17 (27) 27 (44) 0.0078
ically, the p-value for each row compares that row to the distribution in all
Table 4 Number (%) of patients reporting worse, no change, or improved outcomes by treatment
Treatment Symptom improvement Effect of treatment on recovery
n Worse No change Improved p-value n Worse No change Improved p-value
Observation only 1574 612 (39) 507 (32) 455 (29) <0.0001 1514 264 (17) 898 (59) 352 (23) <0.0001
IVMP 1123 363 (32) 192 (17) 568 (51) <0.0001 1122 145 (13) 190 (17) 787 (70) <0.0001
Oral corticosteroids 895 301 (34) 177 (20) 417 (47) <0.0001 894 116 (13) 224 (25) 554 (62) <0.0001
Other 745 237 (32) 160 (21) 348 (47) 0.0005 740 114 (15) 196 (26) 430 (58) <0.0001
IVMP, intravenous methylprednisolone.
Oral corticosteroids include oral methylprednisolone, oral dexamethasone, and oral prednisone. Other includes intramuscular adrenocorticotropic hormone,
intravenous immunoglobulin, plasmapheresis, and other responses.
p-values are for effect of treatment on outcome from Pearson’s chi-square test; specifically, the p-value for each row compares that row to the distribution in all
subjects not in that row.
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treated and oral corticosteroid-treated groups were not
performed. Patient-reported symptom ratings were similar
with IVMP and oral corticosteroids (Figure 3A). Re-
sponses to the question regarding treatment effects had
a similar trend for IVMP and oral corticosteroids, but
there were more positive responses among IVMP-
treated patients (Figure 3B). Notably, approximately
one-third of patients in each group (32% IVMP, 34%
oral corticosteroids) reported that their symptoms were





















































Figure 3 Subjective ratings of (A) symptom improvement and (B) effe
patients. IVMP, intravenous methylprednisolone.treated and 38% of oral corticosteroid-treated patients
reported that treatment resulted in no change or worsened
recovery. Among IVMP-treated and oral corticosteroid-
treated patients, females reported better outcomes than
males. For example, among IVMP-treated patients, symp-
tom ratings of worse, no change, or better were 30%, 17%,
53% for females (n = 943) and were 43%, 19%, 38% for
males (n =180), and treatment effect ratings were 13%,
16%, 71% for females (n = 942) and 13%, 21%, 66% for
males (n =180). Among oral corticosteroid-treated patients,
symptom ratings of worse, no change, or better werehange A Little Better Better Much Better 
orticosteroids (n=895) 
Change A Little Better Better Much Better 
Oral corticosteroids (n=894) 
ct of treatment on recovery among corticosteroid-treated
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41%, 21%, 38% for males (n =136), and treatment effect
ratings were 13%, 24%, 63% for females (n =758) and
13%, 29%, 59% for males (n =136).
Outcomes among patients whose relapses were man-
aged with observation only were generally poorer than
outcomes with treatment. Most (71%) respondents in
this subgroup reported that their symptoms were not
changed or worse than before their relapse (Figure 2A),
and 77% reported that their treatment had no effect or
made their recovery worse (Figure 2B). As with other
treatments, males tended to have less symptom improve-
ment (n = 348; 48% worse, 28% no change, 24% better)
than females (n = 1226; 36% worse, 34% no change, 30%
better) and less treatment efficacy (n = 342; 22% worse,
57% no change, 21% better) than females (n = 1172; 16%
worse, 60% no change, 24% better).
Factors affecting response to treatment
Factors associated with patient-perceived symptoms at 1
month after treatment included sex, number of relapses,
and time since last relapse. The odds of patient-reported
symptoms being “not worse” were lower for males than
females (odds ratio [OR], 0.63; 95% confidence interval
[CI], 0.54-0.75) and for patients with 5 to 9 relapses
(OR, 0.75; 95% CI, 0.64-0.89) or ≥10 relapses (OR, 0.68;
95% CI, 0.58-0.80), compared with those with 1 to 4 re-
lapses, and were higher with a greater number of years
since the last relapse (OR, 1.21; 95% CI, 1.11-1.32)
(Table 5).
Factors associated with patient-reported treatment suc-
cess (ie, responses indicating treatment made recovery
“better” vs “not better”) were sex, time since last relapse,
treatment, and treatment setting. The odds of treatment
success were lower for males than females (OR, 0.81;
95% CI, 0.68-0.96) and higher with a greater number of
years since the last relapse (OR, 1.20; 95% CI, 1.11-1.31),Table 5 Summary of logistic regression results
Outcome Model variables Beta coeffi
Symptoms Sex −0.455
Number of Relapses (5–9) −0.287
Number of Relapses (10+) −0.387
Years Since Most Recent Relapse 0.192
Recovery Sex −0.211
Years Since Most Recent Relapse 0.185
Treatment With IV Steroids 1.306
Treament With Oral Steroids 0.868
Other Treatment 1.095
Treated at Home or Other Nonclinical Site 1.206
Treated at Clinical Site 1.14and with home/nonclinical site treatment (OR, 3.34; 95%
CI, 2.49-4.47) or clinical site treatment (OR, 3.13; 95% CI,
2.36-4.14) compared with patients whose treatment loca-
tion was unspecified. All treatment groups had greater
odds of treatment success compared with observation
only: IV corticosteroids (OR, 3.69; 95% CI, 3.15-4.33), oral
corticosteroids (OR, 2.38; 95% CI, 1.94-2.92), and other
(OR, 2.99; 95% CI, 2.08-4.29) (Table 5).Discussion
This retrospective analysis of data from the NARCOMS
Registry demonstrates that treating relapses results in
better patient-reported outcomes compared with obser-
vation only. However, one-third of patients treated with
the most common treatment, IVMP, reported suboptimal
outcomes in symptom improvement and the effect of
treatment on their recovery. Although some clinicians
may recognize this observation in their practice, phys-
ician and patient perceptions may differ, and the extent
to which patients report suboptimal outcomes has not
been quantified.
It is challenging to compare our findings with other
studies of corticosteroid treatment for MS relapses. Clin-
ical trials of corticosteroid treatment for relapses have
established variable rates of recovery, which may be due
to differences in factors such as how recovery is defined
and the timing of recovery evaluation [17]. In a Cochrane
review of corticosteroids, standardized outcomes were
used to evaluate combined data from 3 studies [18]. Im-
provement in EDSS scores was documented 4 weeks after
treatment in 45% of patients on oral corticosteroids and
59% of patients on IV corticosteroids (consistent with the
percentage of corticosteroid-treated patients reporting
improved symptoms at 1 month after treatment in this
analysis of NARCOMS data); however, improvement
rates in the individual studies ranged from 19% to95% Confidence interval
cient Odds ratio Lower limit Upper limit p-value
0.63 0.54 0.75 <0.001
0.75 0.64 0.89 <0.001
0.68 0.58 0.80 <0.001
1.21 1.11 1.32 <0.001
0.81 0.68 0.96 0.017
1.20 1.11 1.31 <0.001
3.69 3.15 4.33 <0.001
2.38 1.94 2.92 <0.001
2.99 2.08 4.29 <0.001
3.34 2.49 4.47 <0.001
3.13 2.36 4.14 <0.001
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variability in the relapse experience.
Another consideration is that most studies have used
standardized clinician-rated outcome measures, whereas
we have evaluated patient-reported outcomes. Although
several studies have examined changes in, and correlations
among, clinician-rated measures (eg, the EDSS and Mul-
tiple Sclerosis Functional Composite) and patient-rated
HRQoL measures for evaluating response to relapse treat-
ment [19-21], data on patient-perceived recovery are
limited, and agreement between clinician-rated and pa-
tient-reported outcomes can be poor. One study evaluated
outcomes among patients treated with IV corticosteroids
after relapse and included a 5-point Likert-type scale
for patient-reported recovery; 70% of patients reported
improvement (ie, a rating of “somewhat better” or “much
better” than 2 months ago) over an 8-week follow-up
period [22]. This finding is consistent with the 71% of IV
corticosteroid-treated patients reporting that treatment
improved their recovery in our analysis. Hoogervorst
and colleagues reported a slightly higher rate of patient-
reported improvement (78%; 21/27 patients with RRMS)
after treatment with IVMP [23].
In our analysis, several factors affected relapse out-
comes (regardless of treatment), including the number
of previous relapses, time since last relapse, and sex; we
also observed that corticosteroid treatment was associ-
ated with improvement less frequently in males than in
females. Others have observed a greater frequency of
improvement in EDSS scores among females (81%)
compared with males (65%) at 3 months (OR, 2.33; 95%
CI, 1.03–2.56; Mantel-Haenszel p = 0.024) [24], which is
consistent with the lower odds of improvement for males
overall and the lower percentages of improvement in
corticosteroid-treated males in this analysis. However,
Hirst and colleagues [4] reported no effect of sex on
recovery in corticosteroid-treated patients.
In the NARCOMS Registry, 40% of the most recent
relapses were not treated; they were only observed. The
reasons for this finding are unclear, since data were not
collected regarding the reasons for treatment initiation,
specific relapse symptoms, severity of symptoms, or the
extent of disability or impairment of HRQoL associated
with the relapse. Thus, it is possible that many relapses
did not cause enough disability to warrant treatment. In
the study by Hirst and colleagues, only 30.5% of patients
had relapses that required treatment [4], suggesting that
our finding is not unusual. Alternatively, it is possible
that in some instances patients were reluctant to pursue
interventional therapy or to report relapses to their health
care provider but were more likely to report relapse occur-
rence in the survey. However, it is also possible that the
high number of untreated relapses reflects patient dis-
satisfaction with corticosteroid relapse therapy basedon their previous experiences. That is, nearly one-third
of corticosteroid-treated patients felt that the treatment
made their symptoms worse, suggesting that they experi-
enced discomfort related to adverse events; an additional
15% to 20% reported no change in symptoms. As such,
some patients may have previously experienced discom-
fort with corticosteroid-related adverse events or had a
suboptimal response and, therefore, opted not to receive
treatment for the most recent relapse. On a broader level,
there may be an unrecognized propensity for dissatisfac-
tion with corticosteroid treatment as a whole.
Regardless of the reason for the substantial proportion
of untreated relapses, we cannot exclude the possibility
that findings with respect to the extent of symptom im-
provement and effects of treatment on recovery might
have differed had these relapses actually been treated with
corticosteroids. Treatment of relapses appears to improve
patients’ perceptions of recovery in the short term, based
on this large sample of survey respondents. Although
we are unable to address long-term patient-reported
outcomes with these data, treating relapses also may be
important in terms of effects on overall MS outcomes and
HRQoL. For example, Healy and colleagues reported
that relapses were associated with not only reduced
HRQoL at the time of a relapse, but also an overall decline
in patient-rated outcomes over a period of 1 year, com-
pared with patients in remission [25]. Acute relapse treat-
ment with corticosteroids (or ACTH) is not considered to
be disease modifying and has not been shown to result in
long-term benefits [26]. However, evidence that acute
treatment shortens the time to recovery [18] suggests that
corticosteroid interventions help to more quickly resolve
the pathophysiological mechanisms responsible for clinical
relapses. There is evidence that inflammation and demye-
lination are associated with processes that contribute to
long-term disability (ie, axonal damage or loss), that these
processes begin early in the course of MS, and that the ex-
tent of damage increases with the severity of inflammatory
injury [27-29]; if treatment of relapses reduces the extent
of damage by helping to more quickly resolve inflamma-
tory processes, there may be long-term benefits that are
not yet recognized. Thus, the shortening of relapses and
hastening of resolution of symptoms and functional im-
pairment may be associated with greater overall HRQoL,
and effects on the underlying pathophysiological processes
may ultimately benefit patients in the long term.
Limitations of this analysis include the retrospective
nature of data collection and the reliance on patient
recall. It is unlikely that patients were prospectively
documenting their relapses and treatment responses.
Given the mean time since last relapse of 11 months,
most patients had to provide information based on their
recollection of the relapse several months after the fact. In
addition, information on dosage regimen was not reported
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to include dose as an independent variable in order to
evaluate the effect of dosage regimen on outcomes. It is
possible, for example, that the response in males was
worse because they did not have an optimal dosage
regimen or actually require a different regimen. Also, the
questionnaire did not collect information related to the
tolerability of relapse treatments; thus, we are unable to
comment on whether and the extent to which adverse
events contributed to patients’ perceptions of symptom
improvement and treatment effects. Selection bias is also
possible given that only 63.4% of participants returned
the questionnaire; it is unknown whether relapse history
or treatment responses differed between responders
and non-responders. Finally, because patient-reported
outcomes frequently are not standardized, comparisons
between studies can be difficult. These limitations are
offset by the large number of patients included in the
analysis. Although there is variability in some of the results,
the overall perceptions of patients inform clinical care.
Conclusions
Taken together, these data indicate that, to mitigate the
severity of relapse-related pathophysiology and improve
patient HRQoL, it may be necessary to consider alterna-
tives to corticosteroids in RRMS patients who do not
adequately respond to such treatment for a relapse. Clin-
ical and objective measures evaluating the therapeutic
response, side-effect profile, and patient HRQoL follow-
ing relapse treatment regimens are warranted and may
lead to improved relapse management.
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